Upscaling human papillomavirus vaccination in high-income countries: Impact assessment based on transmission model

Infectious Agents and Cancer

Volumn 9, Issue 1, 2014, Pages

  Baussano, Iacopo ^a   Dillner, Joakim ^b   Lazzarato, Fulvio ^c   Ronco, Guglielmo ^d   Franceschi, Silvia ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF TURIN   (Italy)

^d Centre for Cancer Prevention   (Italy)

Author keywords

High income; Human papillomavirus; Mathematical model; Vaccination

Indexed keywords

EID: 84892463356     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-9-4     Document Type: Article

References (32)

1. Male vaccination against human papillomavirus. Salisbury DM, Lancet Infect Dis 2012 12 582 583 10.1016/S1473-3099(12)70082-8 22835890
2. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, Wand H, Fairley CK, Lancet Infect Dis 2011 11 39 44 10.1016/S1473-3099(10)70225-5 21067976
3. Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC), MMWR Morb Mortal Wkly Rep 2011 60 1705 8 22189893
4. Global burden of human papillomavirus and related diseases. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S, Vaccine 2012 30 12 F23 23199955
5. Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study. Georgousakis M, Jayasinghe S, Brotherton J, Gilroy N, Chiu C, Macartney K, Lancet Infect Dis 2012 12 627 634 10.1016/S1473-3099(12)70031-2 22445354
6. Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. French KM, Barnabas RV, Lehtinen M, Kontula O, Pukkala E, Dillner J, Garnett GP, Br J Cancer 2007 96 514 518 10.1038/sj.bjc.6603575 17245341 (Pubitemid 46215226)
7. Health and economic implications of HPV vaccination in the United States. Kim JJ, Goldie SJ, N Engl J Med 2008 359 821 832 10.1056/NEJMsa0707052 18716299
8. Economic evaluation of human papillomavirus vaccination in the United Kingdom. Jit M, Choi YH, Edmunds WJ, BMJ 2008 337 769 10.1136/bmj.a769 18640957
9. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Bogaards JA, Coupe VM, Meijer CJ, Berkhof J, Vaccine 2011 29 8929 8936 10.1016/j.vaccine.2011.09.055 21945961
10. The cost-effectiveness of male HPV vaccination in the United States. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE, Vaccine 2011 29 8443 8450 10.1016/j.vaccine.2011.07.096 21816193
11. Impact of vaccinating boys and men against HPV in the United States. Elbasha EH, Dasbach EJ, Vaccine 2010 28 6858 6867 10.1016/j.vaccine.2010.08.030 20713101
12. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Regan DG, Philp DJ, Hocking JS, Law MG, Sex Health 2007 4 147 163 10.1071/SH07042 17931528 (Pubitemid 47339644)
13. Baussano I, Elfstrom KM, Lazzarato F, Gillio-Tos A, De Marco L, Carozzi F, Del Mistro A, Dillner J, Franceschi S, Ronco G, Type-Specific Human Papillomavirus Biological Features: Validated Model-Based Estimates 8 2013 81171
14. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J, New Technologies for Cervical Cancer screening (NTCC) Working Group, Lancet Oncol 2010 11 249 257 10.1016/S1470-2045(09)70360-2 20089449
15. Sampling and sensitivity analyses tools (SaSAT) for computational modelling. Hoare A, Regan DG, Wilson DP, Theor Biol Med Model 2008 5 4 10.1186/1742-4682-5-4 18304361 (Pubitemid 351514712)
16. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV prevalence surveys. Vaccarella S, Franceschi S, Snijders PJ, Herrero R, Meijer CJ, Plummer M, Cancer Epidemiol Biomarkers Prev 2010 19 503 510 10.1158/1055-9965.EPI-09-0983 20142247
17. Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study. Carozzi F, Ronco G, Gillio-Tos A, De Marco L, Del Mistro A, Girlando S, Franceschi S, Plummer M, Vaccarella S, New Technologies for Cervical Cancer screening (NTCC) Working Group, Eur J Cancer 2012 48 1633 1637 10.1016/j.ejca.2011.10.010 22088483
18. Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica. Vaccarella S, Franceschi S, Herrero R, Schiffman M, Rodriguez AC, Hildesheim A, Burk RD, Plummer M, J Infect Dis 2011 204 385 390 10.1093/infdis/jir286 21742837
19. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G, HPV PATRICIA Study Group, Lancet 2009 374 301 314 10.1016/S0140-6736(09)61248-4 19586656
20. The impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine hpv types in sexually active women aged 16-26 years. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, J Infect Dis 2009 199 936 944 10.1086/597309 19236277
21. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D, N Engl J Med 2011 364 401 411 10.1056/NEJMoa0909537 21288094
22. Tassi di copertura vaccinale per HPV in Italia. Giambi C, IJPH 2011 Vol 8, Num 3 suppl 1 23 27 http://www.ijph.it/pdf/56/023.pdf
23. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, O'Flanagan D, Lopalco PL, D'Ancona F, Levy-Bruhl D, Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, O'Flanagan D, Lopalco PL, D'Ancona F, Levy-Bruhl D, VENICE 2 project gatekeepers group, Euro Surveill 2010 15 47 Available from: URL: http://www.eurosurveillance.org/
24. Giambi C, Stato di avanzamento della campagna vaccinale per l'HPV: dati di copertura vaccinale al 31/12/2010 eaggiornamento delle decisioni in merito alle strategie vaccinali Istituto Superiore di Sanità: Reparto di Epidemiologia di Malattie Infettive del CNESPS http://www.epicentro.iss.it/
25. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. Garnett GP, J Infect Dis 2005 191 Suppl 1 97 106 15627236
26. Reasons for not vaccinating adolescents: National Immunization Survey of Teens, 2008-2010. Darden PM, Thompson DM, Roberts JR, Hale JJ, Pope C, Naifeh M, Jacobson RM, Pediatrics 2013 131 645 651 10.1542/peds.2012-2384 23509163
27. Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Bonanni P, Pesavento G, Bechini A, Tiscione E, Mannelli F, Benucci C, Nostro AL, Vaccine 2003 21 685 691 10.1016/S0264-410X(02)00580-7 12531340 (Pubitemid 36091979)
28. Preventing cancer with vaccines: progress in the global control of cancer. Kane MA, Cancer Prev Res (Phila) 2012 5 24 29 10.1158/1940-6207.CAPR-11- 0533 22219163
29. Human papillomavirus and cervical cancer. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S, Lancet 2007 370 890 907 10.1016/S0140-6736(07)61416-0 17826171 (Pubitemid 47371147)
30. HPV vaccine for all. Michels KB, Zur Hausen H, Lancet 2009 374 268 270 10.1016/S0140-6736(09)61247-2 19586657
31. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, Abrahamsen M, Salmeron J, Anic GM, Rollison DE, Smith D, Lancet 2011 377 932 940 10.1016/S0140-6736(10)62342-2 21367446
32. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S, CVT Vaccine Group, J Natl Cancer Inst 2011 103 1444 1451 10.1093/jnci/djr319 21908768